dupix surpris street swing
hit overhang remain
dupix sale posit surpris actual beat estim
dupix swing ballpark sale significantli higher consensu
estim actual vs consensu accord manag sale
higher mostli due increas demand us adult atop dermat adult
asthma launch adolesc atop dermat patient howev think
beat could also inventori shift also optimist
dupix sale base prior physician survey remain cautiou
ipr/litig overhang on-going look toward resolut disput
settlement ex-u sale dramat differ consensu number
eylea growth could temporari avastin shortag
eylea sale beat consensu estim vs think
higher expect sale temporari due avastin shortag
geographi furthermor avastin shortag resolv next quarter
think eylea growth slow addit price concern part reform
potenti eu basket price competit join market nv brolucizumab
exampl believ eylea sale growth risk largest sell product
believ risk revenu pose signific risk share
opex continu expect much higher spend
expect oper expens remain higher year year basi
compani continu spend clinic develop increas headcount
manufactur cost believ cost larg unavoid compani
like continu spend current base rate includ one time up-
front alynylam expens non-cash expens forese futur
spend constitut major spend increas sg play smaller role
achiev compani non-gaap unreimburs low end guidanc
second half spend exceed suggest may cut spend
first half
base view consensu number bit high maintain hold
rate pt note sever headwind compani
includ dupix patent ipr/litig continu price concern eylea
medicar part price initi addit eylea competit join fray
potenti year-end continu expect strong growth dupix
moder growth eylea may diminish competit product obtain greater
market share time
price close busi august
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
actualconsensuscanaccordconsensuscanaccordeylea- ex collabor collabor product profit incom ep fulli ep fulli cemiplimabregulatori regulatori decis libtayo advanc cscccompletedpdufa date dupix adolesc ad completeddata data dupix pediatr date eylea npdr patient w/o dme completedpdufa date praluent cardiovascular risk reductioncompletedpdufa date praluent first-lin hyperlipidemia complet figur valuat summari
free projectionsebit use un-reimburs yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate figur revenu build
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu ex-u figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch reimburs sanofi bayer teva option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli epsbas share dilut share outstand dilut share outstand figur balanc sheet
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
